ASTH

Astrana Health, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Care Facilities

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/06/2026

Business Summary

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.

 


VALUATION

P/E

61.94

Market Cap ($M USD)

$1.90B

Forward P/E

10.71

PEG

0.02

PRICE TO SALES

0.54

PRICE TO BOOK

2.34

EV / EBITDA

16.71

5-Year Average P/E

Free Cash Flow Yield

8.16%

DCF Value

$54.06

Graham Number

$15.10

Price to FCF

12.26

EV to FCF

16.05

Earnings Yield

1.61%

FCF Yield

8.16%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

8.38%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.62

Next Year EPS Growth Estimate

$3.58

Next Year Revenue Growth Estimate

$548.54B

Return on Equity (ROE)

3.88%

FREE CASH FLOW

Operating Margin

2.45%

Debt-to-Equity

1.38

Piotroski F-Score

5

Altman Z-Score

2.59

Return on Invested Capital (ROIC)

5.36%

Current Ratio

1.35

Quick Ratio

1.35

Net Debt to EBITDA

3.94

Interest Coverage

1.47

Gross Profit margin

9.31%

FCF PER SHARE

$3.17

REVENUE PER SHARE

$72.18

Gainseekers Quantitative Analysis

Summary

Astrana Health, Inc. appears to be a classic case of market mispricing. Despite a snapshot price that traded well below its DCF value, the company boasts a robust forward P/E ratio, suggesting significant earnings growth potential. The Altman Z-score indicates moderate financial health, while the earnings yield is modest, hinting at a cautious optimism from investors. The Graham Number further underscores the undervaluation, presenting a compelling opportunity for value investors. Overall, the financial health seems stable, but the market may be underestimating its future prospects.

AI Exposure / Tech Reliance

In the rapidly evolving healthcare sector, Astrana Health is strategically positioned to leverage AI and modern technology. As a medical care facility, the integration of AI can enhance patient care and operational efficiency. This adaptability is crucial for maintaining competitiveness in an industry increasingly driven by technological advancements.

The Bull Case

For the discerning GARP investor, Astrana Health offers a tantalizing proposition. With a forward PEG ratio well below 1, the stock is priced attractively relative to its growth prospects. The ROIC and FCF yield indicate efficient capital allocation and cash generation, while a Piotroski F-Score of 5 suggests moderate financial strength. These metrics collectively paint a picture of a company with solid pricing power and operational efficiency, making it a potential gem for value seekers.

The Bear Case

Despite its strengths, Astrana Health is not without its pitfalls. The high Price/Earnings ratio raises concerns about overvaluation, especially when juxtaposed with a modest operating margin. The company’s proximity to its 52-week high suggests technical overextension, which could deter cautious investors. Additionally, the gross profit margin is underwhelming, indicating potential challenges in cost management and competitive pricing.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$44.60

Institutional Ownership %

1-Year Beta

0.99

Insider Buying % (6 Mo)

Distance to 52-Week High

4.17%

Distance to 52-Week Low

52.83%

EARNINGS SURPRISE %

155.17%

50-DAY SMA

$31.97

200-DAY SMA

$27.68

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.